Literature DB >> 29408171

Serum S100A12 as a prognostic biomarker of severe traumatic brain injury.

Ma-Jing Feng1, Wei-Bin Ning2, Wei Wang2, Zhong-Hua Lv2, Xin-Bing Liu2, Yong Zhu2, Wei Gao2, Hong-Ze Jin2, Shu-Shan Gao2.   

Abstract

BACKGROUND: S100A12 is related to acute brain injury and inflammation. We investigated the clinical prognostic value of serum S100A12 in patients with severe traumatic brain injury (sTBI).
METHODS: Serum S100A12, S100B, C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α) concentrations were measured in 102 healthy controls and 102 sTBI patients. We recorded 30-day mortality and in-hospital major adverse events (IMAEs) including acute lung injury, acute traumatic coagulopathy, progressive hemorrhagic injury and posttraumatic cerebral infarction. Trauma severity was assessed by admission Glasgow Coma Scale scores.
RESULTS: When compared to the controls, serum S100A12, S100B, CRP, IL-6 and TNF-α concentrations were significantly increased in the patients. Serum concentrations of S100A12 significantly correlated with admission Glasgow Coma Scale scores and serum concentrations of S100B, CRP, IL-6 and TNF-α. Patients with any IMAEs or non-survivors within 30 days had obviously higher serum concentrations of S100A12, S100B, CRP, IL-6 and TNF-α than other remaining ones. Serum S100A2 was independently associated with IMAEs and 30-day mortality and overall survival. Receiver operating characteristic curve analysis showed that S100A12 concentrations had significant discriminatory ability for patients at risk of any IMAEs and death within 30 days.
CONCLUSION: S100A12 might be associated with brain inflammation and evaluation of serum concentrations of S100A12 could be helpful in the early prognostic prediction in sTBI patients.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Inflammation; Prognosis; S100A12; Severity; Traumatic brain injury

Mesh:

Substances:

Year:  2018        PMID: 29408171     DOI: 10.1016/j.cca.2018.01.044

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

1.  Interleukin-6 as a prognostic biomarker of clinical outcomes after traumatic brain injury: a systematic review.

Authors:  Setthasorn Zhi Yang Ooi; Robert James Spencer; Megan Hodgson; Samay Mehta; Nicholas Lloyd Phillips; Gwilym Preest; Susruta Manivannan; Matt P Wise; James Galea; Malik Zaben
Journal:  Neurosurg Rev       Date:  2022-07-06       Impact factor: 2.800

Review 2.  Systematic Review of Serum Biomarkers in Traumatic Brain Injury.

Authors:  Khashayar Mozaffari; Dillon Dejam; Courtney Duong; Kevin Ding; Alexis French; Edwin Ng; Komal Preet; Alyssa Franks; Isabelle Kwan; H Westley Phillips; Dennis Y Kim; Isaac Yang
Journal:  Cureus       Date:  2021-08-10

3.  Relation of postoperative serum S100A12 levels to delirium and cognitive dysfunction occurring after hip fracture surgery in elderly patients.

Authors:  Qing-Hua Li; Liang Yu; Zheng-Wei Yu; Xiao-Liang Fan; Wang-Xiang Yao; Cheng Ji; Fang Deng; Xian-Zhe Luo; Jian-Liang Sun
Journal:  Brain Behav       Date:  2018-12-11       Impact factor: 2.708

4.  High Serum S100A12 Levels Predict Poor Outcome After Acute Primary Intracerebral Hemorrhage.

Authors:  Shen-Zhong Qiu; Guan-Rong Zheng; Cai-Yan Ma; Bin Chen; Jian-Jun Huang; Ge Huang; Hai Hua
Journal:  Neuropsychiatr Dis Treat       Date:  2021-11-02       Impact factor: 2.570

5.  Association of the inflammation-related proteome with dementia development at older age: results from a large, prospective, population-based cohort study.

Authors:  Kira Trares; Megha Bhardwaj; Laura Perna; Hannah Stocker; Agnese Petrera; Stefanie M Hauck; Konrad Beyreuther; Hermann Brenner; Ben Schöttker
Journal:  Alzheimers Res Ther       Date:  2022-09-09       Impact factor: 8.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.